CTN: Clinical Trial Notification, IND: Investigational New Drug, IB: Investigator Brochure, PICF: Participant Information and Consent Form, IBC: Institutional Biosafety Committee, FDA: Food and Drug Administration, EMA: European Medicines Agency, KOL: Key Opinion Leader Insight Brief Clinical Development of Cell and Gene Therapy (CAGT) Products in Australia Table of contents | Why Australia for CAGT trials? | 1 | | --- | --- | | Mature R&D ecosystem | 2 | | Established and favorable regulatory pathway in Au ...

White Paper Optimizing Early-Phase Clinical Trials for Rapid, Evidence- Based Decision Making Leveraging the rapidly evolving design and delivery strategies to safely accelerate molecule advancement ELIZABETH ALLEN, PhD, Vice-President, Early Phase Development Centre of Excellence, Scientific Strategy RAYMOND COOK, MD, Vice President, Medical Strategy for Early Phase Development JOANNE EMANUEL, Senior Director, Clinical Project Management, Early Phase JOCHEN ZESCHKY, Senior Therapeutic Strategy Lead Directo ...

Key Takeaways IQVIA beat Q4 earnings and revenue estimates, delivering 9.6% EPS growth and 10.3% Y/Y revenue rise.IQV posted segment gains: R&D and Technology & Analytics grew about 10%, while Contract Sales surged 18.6%.IQVIA guided 2026 revenues at $17.15-$17.35B and reported $2B cash with $561M in Q4 free cash flow.IQVIA Holdings Analytics Inc. (IQV) has reported impressive fourth-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings were $3.42 per share, ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - Senior VP of Investor Relations and TreasuryMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Resear ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - VP of Investor RelationsMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Research AnalystJustin Bow ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Speaker7Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would ...

IQVIA Holdings (IQV) came out with quarterly earnings of $3.42 per share, beating the Zacks Consensus Estimate of $3.4 per share. This compares to earnings of $3.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.50%. A quarter ago, it was expected that this clinical testing company would post earnings of $2.96 per share when it actually produced earnings of $3, delivering a surprise of +1.35%.Over the last four quarters, t ...

Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall Street expectations, weighed down by higher interest costs, even as strong fourth-quarter re... ...

Q4 2025 Earnings Call February 5, 2026 © 2026. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. IQVIA Template (V4.0.0) 100% 50% 75% 25% Bright Blue Indigo Bright Teal Bright Green Emerald 5% Charcoal Red Legal 2 IQVIA Template (V2.1.0) 100% 50% 75% 25% This presentation should be viewed in conjunction with IQVIA's Q4 2025 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "fo ...

Exhibit 99.1 IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance RESEARCH TRIANGLE PARK, N.C. – February 5, 2026 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025. "IQVIA closed 2025 with strong performance across all segments," said Ari Bousbib, chairman ...